ANNX - Annexon, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
ANNX price evolution
ANNX
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $9.96 | $2.94 | $11.45 | |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $344.29 | $373.97 | $270.74 | $263.86 |
| Long term investments | ||||
| Property, plant & equipment | $30.22 | $31.08 | $31.94 | $32.78 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $378.78 | $406.08 | $304.07 | $297.67 |
| Current liabilities | ||||
| Accounts payable | $6.75 | $4.13 | $3.97 | $5.49 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $20.05 | $17.15 | $13.13 | $17.93 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $47.22 | $45.01 | $41.66 | $47.12 |
| Shareholders' equity | ||||
| Retained earnings | -$662.11 | -$627.28 | -$597.67 | -$572.5 |
| Other shareholder equity | $0.08 | -$0.09 | -$0.1 | -$0.05 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $268.56 | |||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $263.86 | $248.1 | $247.69 | $354.01 |
| Long term investments | ||||
| Property, plant & equipment | $32.78 | $35.97 | $38.18 | $1.94 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $1.94 | |||
| Total investments | ||||
| Total assets | $297.67 | $285.1 | $287.04 | $355.95 |
| Current liabilities | ||||
| Accounts payable | $5.49 | $7.42 | $11.15 | $3.73 |
| Deferred revenue | $0.39 | |||
| Short long term debt | ||||
| Total current liabilities | $17.93 | $22.36 | $21.74 | $10.62 |
| Long term debt | ||||
| Total noncurrent liabilities | $1.05 | |||
| Total debt | ||||
| Total liabilities | $47.12 | $53.9 | $55.13 | $11.67 |
| Shareholders' equity | ||||
| Retained earnings | -$572.5 | -$438.26 | -$296.31 | -$165.99 |
| Other shareholder equity | -$0.05 | -$0.37 | -$0.18 | -$0.08 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $39.44 | $33.58 | $28.57 | $30.01 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $4.62 | $3.97 | $3.4 | $2.12 |
| Net income | ||||
| Net income | -$34.82 | -$29.61 | -$25.18 | -$27.89 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $143.72 | $145.6 | $63.47 | |
| Operating income | -$63.47 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $9.49 | |||
| Net income | ||||
| Net income | -$134.24 | -$141.95 | -$63.41 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$219.81 | -$173.88 | -$77.3 | $70.7 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $156.24 | $156.06 | $32.41 | $135.52 |
| Effect of exchange rate | -$0.01 | -$0.01 | -$0.01 | $0.01 |
| Change in cash and equivalents | -$145.57 | -$67.81 | -$73.17 | $85.09 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$63.41 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$53.09 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $70.7 | $58.44 | -$88.24 | -$83.16 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $135.52 | $122.91 | $1.79 | $360.88 |
| Effect of exchange rate | $0.01 | -$0.01 | $0.01 | |
| Change in cash and equivalents | $85.09 | $65.04 | -$192.57 | $224.63 |
News
Fundamentals
| Market cap | $552.86M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 105.71M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$117.50M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -4.71 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.09 |
| EPS | -$1.11 |
|---|---|
| ROA | -33.90% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 17.18 |
| Quick ratio | N/A |